In this study we report the safety and effects of oral ribose supplementation during 6 months in a patient with LGMD type 2I (LGMD2I) due to a homozygous FKRP mutation. The gene discussed is FKRP; the disease is autosomal recessive limb-girdle muscular dystrophy type 2I.